Search

Your search keyword '"Ding, Pei-Rong"' showing total 378 results

Search Constraints

Start Over You searched for: Author "Ding, Pei-Rong" Remove constraint Author: "Ding, Pei-Rong" Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
378 results on '"Ding, Pei-Rong"'

Search Results

3. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study

4. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

6. Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.

8. Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer

10. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial

11. Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial

12. Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment

26. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer

28. Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial

29. Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC)

32. Multi-omics analyses of single cell-derived colorectal cancer organoids reveal intratumor heterogeneity and immune response diversity

33. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study

35. Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning

38. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bm0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study

40. Additional file 2 of High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer

41. Additional file 1 of High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer

43. SONCAR study: A prospective randomized controlled study on optimized neoadjuvant chemotherapy-oxaliplatin plus CRT in patients with locally advanced rectal cancer.

47. Inflammatory Conditions Promote Resistance to Immune Checkpoint Inhibitors in High Microsatellite Instability Colorectal Cancer

48. Corrigendum to “Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer” [Canc. Lett. 500 (2021) 119-131]

Catalog

Books, media, physical & digital resources